Hosted on MSN
VMS TMT IPO allotment date likely today. Latest GMP, step-by-step guide to check share allotment status online
VMS TMT IPO Allotment: The initial public offering (IPO) of Thermo Mechanically Treated Bars (TMT Bars) manufacturer VMS TMT Ltd was subscribed by a massive 102 times. Investors now await VMS TMT IPO ...
Corning Incorporated (NYSE:GLW) is one of the best multibagger stocks to invest in according to billionaires. On March 11, Corning Incorporated announced a collaboration with US Conec to become a ...
Wells Fargo raised its Merck price target to $150, betting that sac-TMT’s potential to displace chemotherapy across multiple cancer indications, combined with KEYTRUDA’s continued growth and a ...
Artificial intelligence (AI) has become the central force reshaping mergers and acquisitions in the technology, media, and telecom (TMT) sector. Global deal value surged 76 per cent in 2025 to $903 ...
Bank of America clients turned net buyers of U.S. equities last week for the first time in eight weeks, driven by dip-buying in technology, media, and telecommunications stocks even as institutional ...
FORT CARSON, Colo. — As George Floyd surveys the terrain of Range 127, he reflects on his career as an Infantryman and how training has evolved exponentially to meet the demands of current and future ...
Merck cholesterol pill enlicitide and cancer therapy sac-TMT tapped for new priority program FDA expects Merck to submit applications in April and autumn of 2026, documents show Both drugs if approved ...
Dec 15 (Reuters) - Goldman Sachs (GS.N), opens new tab is restructuring its influential technology, media, and telecom (TMT) investment banking group with an eye toward infrastructure deals and ...
With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...
Sac-TMT combined with Keytruda significantly improves progression-free survival in PD-L1-positive advanced non-small cell lung cancer. The OptiTROP-Lung05 study is the first phase 3 trial of an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results